The curative effects of metformin in polycystic ovary syndrome patients with obese and without obese

SHI Shao-quan,JIANG Fang-fang,HONG Ting,WANG Gui-rong,WANG Feng
DOI: https://doi.org/10.16386/j.cjpccd.issn.1004-6194.2013.05.029
2013-01-01
Abstract:Objective To explore the efficacy of metformin for improving the endocrine and reproductive function in polycystic ovary syndrome(PCOS) patients with obese and without obese. Methods Eighty four infertility patients with PCOS(48 cases with obese and 36 cases without obese) were treated with metformin at a dose of 1 500 mg daily for 3 menstrual cycles. The clinical and endocrine changes were compared before and after treatment. The ovulation rate and pregnancy rate of subjects treated by metformin were recorded, and compared with the ovulation rate and pregnancy rate of 35 PCOS cases(18 cases with obese and 17cases without obese) treated by clomiphene citrate(CC). Results After treatment of metformin for three menstrual cycles, the BMI,WHR, total testosterone and fast insulin and luteinizing hormone(LH)/follicle stimulate hormone(FSH) in PCOS patients with obese decreased significantly(P<0.05 or P<0.01), but the decreases of those indexes in PCOS patients without obese were not obvious(P>0.05). After treatment for three menstrual cycles, although the cumulative ovulation rate in metformin group was higher than that in CC group, there was no significant difference(P>0.05). The cumulative pregnancy rates in metformin group with obese and CC group with obese were 54.17%(26/48) and 27.78%(5/18), respectively; the cumulative pregnancy rates in metformin group without obese and CC group without obese were 58.33%(21/36) and 29.41%(5/17), respectively. The cumulative pregnancy rate in metformin group was significantly higher than that in CC group(P<0.05). Conclusion Metformin could improve the endocrine condition,boost the ovulation and increase the pregnancy rates in PCOS patients.
What problem does this paper attempt to address?